Neurology
Partner With Us
Advertisement
Conexiant chevron_right Neurology chevron_right A Trio of Trials Track Early Migraine Drug Response
From the Journals FDA & Government News

Trio of Trials Track Early Migraine Drug Response

Day 1 efficacy data from 3 trials reveal atogepant's rapid impact in reducing migraine frequency, with functional improvements as early as week 1.

Conexiant
article Full Article subject Summary summarize Notecard
  1. Atogepant demonstrated efficacy in reducing migraine frequency and improving functional outcomes and quality of life. 
  2. Treatment-emergent adverse events occurred in a considerable percentage of atogepant-treated patients.
  3. The study was funded by AbbVie, and multiple authors disclosed relationships with pharmaceutical companies.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.